Okamoto Naoyuki, Saruki Nobuhiro, Mikami Haruo, Yamashita Kousuke, Maruyama Yoichi, Yano Tokujiro, Imamura Yuka, Kaneko Satoshi, Tanaka Hideo
Division of Cancer Prevention and Cancer Control, Kanagawa Cancer Center, Yokohama 241-0815, Japan.
Asian Pac J Cancer Prev. 2006 Jan-Mar;7(1):46-50.
In Japan, The Japanese Association of Clinical Cancer Centers (JACCCs) was established in 1965 by systematizing cancer-treatment-oriented hospitals. The core center of JACCCs is the National Cancer Center in Tokyo. In 1984, JACCCs created The "Improvement for Clinical Cancer Centers in Japan" Study Group (The Study Group) which has subsequently routinely evaluated the effectiveness of the therapy that is provided. In general, the 5-year (relative) survival rate is employed as an indicator of the treatment efficacy. The present survey used the PC software program KAP developed by Chiba Cancer Center in Japan, to calculate 5-year observed survival rates and the 5-year relative survival rates using Ederer II methods. The overall 5-year relative survival rates in patients with stomach (15,353 patients), colon (5,054), rectum (3,695), lung (10,153), breast (11,302) and cervix of the uterus (6,336) were 68.7%, 72.2%, 69.4%, 28.1%, 86.1% and 81.1%, respectively. The survival rates discussed so far are principally observed survival rates. The 5-year relative survival rate for those institutions that specialize in cancer treatment should become an index for Japanese cancer treatment.
在日本,日本临床癌症中心协会(JACCCs)于1965年通过将以癌症治疗为导向的医院系统化而成立。JACCCs的核心中心是东京的国立癌症中心。1984年,JACCCs成立了“日本临床癌症中心改进”研究小组(该研究小组),此后定期评估所提供治疗的有效性。一般来说,5年(相对)生存率被用作治疗效果的指标。本次调查使用了日本千叶癌症中心开发的PC软件程序KAP,采用埃德勒二世方法计算5年观察生存率和5年相对生存率。胃癌(15353例患者)、结肠癌(5054例)、直肠癌(3695例)、肺癌(10153例)、乳腺癌(11302例)和子宫颈癌(6336例)患者的总体5年相对生存率分别为68.7%、72.2%、69.4%、28.1%、86.1%和81.1%。到目前为止讨论的生存率主要是观察到的生存率。那些专门从事癌症治疗的机构的5年相对生存率应成为日本癌症治疗的一个指标。